Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe and life-threatening adverse drug reactions. Herein we report about a patient with head and neck cancer, who developed SJS-TEN overlap after having received cetuximab and radiotherapy. To date, there are only two reports of TEN associated with cetuximab therapy in patients with cancer. Every skin condition in a patient with cancer leading to extensive exfoliation of the skin should alert the oncologist of a possibility of drug-induced SJS or TEN.
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. mirjana.urosevic@usz.ch
Mirjana
M
Urosevic-Maiwald
Thomas
T
Harr
Lars E
LE
French
Reinhard
R
Dummer
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000009:adverse effects; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D011855:Radiodermatitis / Q000209:etiology; D013262:Stevens-Johnson Syndrome / Q000150:complications* / Q000188:drug therapy / Q000209:etiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D000068818:Cetuximab